Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Revvity (NYSE:RVTY) reported Q2 results largely in line with expectations, achieving 3% organic growth. Performance was bifurcated, with Life Sciences delivering mid-single-digit growth driven by strong software and sequential reagents momentum, while Diagnostics saw low single-digit growth. The company's overall outlook was slightly lowered, primarily attributed to weakness in China Diagnostics.

Analysis

Revvity's second-quarter performance was largely in line with expectations, delivering 3% organic growth. However, this headline figure masks a notable divergence between its main business units. The Life Sciences division outperformed with mid-single-digit growth, propelled by strong performance in its software business and positive sequential momentum in reagents, indicating a partial recovery. In contrast, the Diagnostics division posted weaker, low-single-digit growth. This underperformance, specifically attributed to weakness in the China Diagnostics market, was the primary driver behind management's decision to lower its forward-looking outlook. The overall tone from CFO Maxwell Krakowiak is cautious, balancing the solid execution in Life Sciences against the significant and specific geographic headwinds impacting the Diagnostics segment.

Key Decisions for Investors

• Investors should closely monitor the performance gap between the strong Life Sciences segment and the underperforming Diagnostics division, as the former's momentum is key to offsetting weakness.
• The lowered guidance attributed specifically to China Diagnostics makes this a critical risk factor; any signs of stabilization or further deterioration in that market will likely be a primary driver for the stock.
• Given the mixed results, it is prudent to assess whether Revvity's current valuation adequately reflects the headwinds in Diagnostics against the underlying strength and recovery trends in its Life Sciences portfolio.